Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 2/2015

01-02-2015 | Invited Commentary

Dietary Sodium: Where Science and Policy Conflict: Impact of the 2013 IOM Report on Sodium Intake in Populations

Author: Niels Graudal

Published in: Current Hypertension Reports | Issue 2/2015

Login to get access

Abstract

The 2013 Institute of Medicine (IOM) report “Sodium Intake in Populations: Assessment of Evidence” did not support the current recommendations of the IOM and the American Heart Association (AHA) to reduce daily dietary sodium intake to below 2300 mg. The report concluded that the population-based health outcome evidence was not sufficient to define a safe upper intake level for sodium. Recent studies have extended this conclusion to show that a sodium intake below 2300 mg/day is associated with increased mortality. In spite of this increasing body of evidence, the AHA, Centers for Disease Control (CDC), other public health advisory bodies, and major medical journals have continued to support the current policy of reducing dietary sodium.
Literature
1.
IOM. (Institute of Medicine). Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. Washington, DC: National Academies Press; 2005.
2.
IOM. (Institute of Medicine). Dietary reference intakes: essential guide to nutrient requirements. Washington, DC: National Academies Press; 2006.
3.
IOM. (Institute of Medicine). Sodium intake in populations: assessment of evidence. Washington, DC: National Academies Press; 2013.
4.
Gunn JP, Barron JL, Bowman BA, Merritt RK, Cogswell ME, Angell SY, et al. Sodium reduction is a public health priority: reflections on the Institute of Medicine’s report, sodium intake in populations: assessment of evidence. AJH. 2013;26:1178–80.PubMed
5.
Cobb LK, Anderson CA, Elliott P, Hu FB, Liu K, Neaton JD, et al. Methodological issues in cohort studies that relate sodium intake to cardiovascular disease outcomes: a science advisory from the American Heart Association. Circulation. 2014;129:1173–86.CrossRefPubMed
6.
Whelton PK, Appel LJ, Sacco RL, Anderson CA, Antman EM, Campbell N, et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation. 2012;126:2880–9.CrossRefPubMed
7.
Pfister R, Michels G, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Estimated urinary sodium excretion and risk of heart failure in men and women in the EPIC-Norfolk study. Eur J Heart Fail. 2014 Jan 20. doi:10.​1002/​ejhf.​56. [Epub ahead of print].
8.
Graudal N, Jürgens G, Baslund B, Alderman MH. Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. Am J Hypertens. 2014;27:1129–37.CrossRefPubMed
9.
O’Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med. 2014;371:612–23.CrossRefPubMed
10.
Graudal NA, Galløe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols. JAMA. 1998;279:1383–91.CrossRefPubMed
11.
Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev. 2011;11, CD004022.PubMed
12.
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012;11, CD002003.PubMed
13.
Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease. Am J Hypertens. 2011;24:843–53.CrossRefPubMed
14.
Mente A, O’Donnell MJ, Rangarajan S, McQueen MJ, Poirier P, Wielgosz A, et al. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med. 2014;371:601–11.CrossRefPubMed
15.
Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441–9.CrossRefPubMed
16.
Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010;362:590–9.CrossRefPubMedCentralPubMed
17.
Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371:624–34.CrossRefPubMed
18.
Thomas MC, Moran J, Forsblom C, Harjutsalo V, Thorn L, Ahola A, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34:861–6.CrossRefPubMedCentralPubMed
19.
O’Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306:2229–38.PubMed
20.
The Trials of Hypertension Prevention Collaborative Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. JAMA. 1992;267:1213–20.CrossRef
21.
The Trials of Hypertension Prevention Collaborative Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention Phase II. Arch Intern Med. 1997;157:657–67.CrossRef
22.
Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH–Sodium Collaborative Research Group. NEJM. 2001;344:3–10.CrossRefPubMed
23.
Appel LJ, Espeland MA, Easter L, Wilson AC, Folmar S, Lacy CR. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med. 2001;161:685–93.CrossRefPubMed
24.
He F, MacGregor G. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens. 2002;16:761–70.CrossRefPubMed
25.
Wright JD, Hughes JP, Ostchega Y, Yoon SS, Nwankwo T. Mean systolic and diastolic blood pressure in adults aged 18 and over in the United States; 2001–2008. National Health Statistics Report; 35: 1–24.
26.
He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet. 2011;378:380–2.CrossRefPubMed
27.
He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA. 1999;282:2027–34.CrossRefPubMed
28.
Yang Q, Liu T, Kuklina EV, Flanders WD, Hong Y, Gillespie C et al. Sodium and potassium intake and mortality among US adults: prospective data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2011;171:1183–91.
29.
Elliott P, Stamler J, Nichols R, Dyer AR, Stamler R, Kesteloot H, et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ. 1996;312:1249–53.CrossRefPubMedCentralPubMed
30.
Kaiser J. Industry groups petition for data on salt and hypertension. Science. 2003;300:1350.
31.
Graudal N. Sodium and cardiovascular disease. N Engl J Med. 2014;371:2136–7.
Metadata
Title
Dietary Sodium: Where Science and Policy Conflict: Impact of the 2013 IOM Report on Sodium Intake in Populations
Author
Niels Graudal
Publication date
01-02-2015
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 2/2015
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-014-0522-0

Other articles of this Issue 2/2015

Current Hypertension Reports 2/2015 Go to the issue

Blood Pressure Monitoring and Management (J Cockcroft, Section Editor)

The Sympathetic Nervous System in Hypertension: Back to the Future?

Hypertensive Emergencies (BM Baumann, Section Editor)

Cardiovascular Hypertensive Emergencies

Hypertension and the Kidney (RM Carey, Section Editor)

Neuroprotective Mechanisms of the ACE2–Angiotensin-(1-7)–Mas Axis in Stroke

Pathogenesis of Hypertension (W Elliott, Section Editor)

Dietary Factors and Higher Blood Pressure in African-Americans

Hypertension and Obesity (E Reisin, Section Editor)

The Impacts of Obesity on the Cardiovascular and Renal Systems: Cascade of Events and Therapeutic Approaches

Pathogenesis of Hypertension (W Elliott, Section Editor)

The Clinical Relevance of the Percentage Flow-Mediated Dilation Index
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits